Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
Release of immunoreactive negative regulatory factors such as immune checkpoint limits antitumor responses. PD-L1 as a significant immunosuppressive factor has been involved in resistance to therapies such as chemotherapy and target therapy in various cancers. Via interacting with PD-1, PD-L1 can re...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/4/663 |
| _version_ | 1797413313953398784 |
|---|---|
| author | Yu Yuan Abdalla Adam Chen Zhao Honglei Chen |
| author_facet | Yu Yuan Abdalla Adam Chen Zhao Honglei Chen |
| author_sort | Yu Yuan |
| collection | DOAJ |
| description | Release of immunoreactive negative regulatory factors such as immune checkpoint limits antitumor responses. PD-L1 as a significant immunosuppressive factor has been involved in resistance to therapies such as chemotherapy and target therapy in various cancers. Via interacting with PD-1, PD-L1 can regulate other factors or lead to immune evasion of cancer cells. Besides, immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in the different tumors, but a significant percentage of patients cannot benefit from this therapy due to primary and acquired resistance during treatment. In this review, we described the utility of PD-L1 expression levels for predicting poor prognosis in some tumors and present evidence for a role of PD-L1 in resistance to therapies through PD-1/PD-L1 pathway and other correlating signaling pathways. Afterwards, we elaborate the key mechanisms underlying resistance to PD-1/PD-L1 blockade in cancer immunotherapy. Furthermore, promising combination of therapeutic strategies for patients resistant to PD-1/PD-L1 blockade therapy or other therapies associated with PD-L1 expression was also summarized. |
| first_indexed | 2024-03-09T05:15:51Z |
| format | Article |
| id | doaj.art-4cd62c837f984fd0853920803698718d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T05:15:51Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-4cd62c837f984fd0853920803698718d2023-12-03T12:45:18ZengMDPI AGCancers2072-66942021-02-0113466310.3390/cancers13040663Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade ImmunotherapyYu Yuan0Abdalla Adam1Chen Zhao2Honglei Chen3Department of Pathology and Hubei Province Key Laboratory of Allergy and Immune-Related Diseases, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, ChinaDepartment of Pathology and Hubei Province Key Laboratory of Allergy and Immune-Related Diseases, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, ChinaDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaDepartment of Pathology and Hubei Province Key Laboratory of Allergy and Immune-Related Diseases, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, ChinaRelease of immunoreactive negative regulatory factors such as immune checkpoint limits antitumor responses. PD-L1 as a significant immunosuppressive factor has been involved in resistance to therapies such as chemotherapy and target therapy in various cancers. Via interacting with PD-1, PD-L1 can regulate other factors or lead to immune evasion of cancer cells. Besides, immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in the different tumors, but a significant percentage of patients cannot benefit from this therapy due to primary and acquired resistance during treatment. In this review, we described the utility of PD-L1 expression levels for predicting poor prognosis in some tumors and present evidence for a role of PD-L1 in resistance to therapies through PD-1/PD-L1 pathway and other correlating signaling pathways. Afterwards, we elaborate the key mechanisms underlying resistance to PD-1/PD-L1 blockade in cancer immunotherapy. Furthermore, promising combination of therapeutic strategies for patients resistant to PD-1/PD-L1 blockade therapy or other therapies associated with PD-L1 expression was also summarized.https://www.mdpi.com/2072-6694/13/4/663PD-L1resistanceimmune checkpointsimmunotherapy |
| spellingShingle | Yu Yuan Abdalla Adam Chen Zhao Honglei Chen Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy Cancers PD-L1 resistance immune checkpoints immunotherapy |
| title | Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy |
| title_full | Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy |
| title_fullStr | Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy |
| title_full_unstemmed | Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy |
| title_short | Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy |
| title_sort | recent advancements in the mechanisms underlying resistance to pd 1 pd l1 blockade immunotherapy |
| topic | PD-L1 resistance immune checkpoints immunotherapy |
| url | https://www.mdpi.com/2072-6694/13/4/663 |
| work_keys_str_mv | AT yuyuan recentadvancementsinthemechanismsunderlyingresistancetopd1pdl1blockadeimmunotherapy AT abdallaadam recentadvancementsinthemechanismsunderlyingresistancetopd1pdl1blockadeimmunotherapy AT chenzhao recentadvancementsinthemechanismsunderlyingresistancetopd1pdl1blockadeimmunotherapy AT hongleichen recentadvancementsinthemechanismsunderlyingresistancetopd1pdl1blockadeimmunotherapy |